Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P010033/S051

QuantiFERON-TB Gold Plus Test

Qiagen · Decision date Nov 21, 2025

FDA DECISIONP010033/S051

What did the FDA approve?

FDA records P010033/S051 as a supplement to PMA P010033, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 21, 2025.

FDA approval order statement

Approval for a design change to the device TB Antigen blood collection tubes (QuantiFERON TB Gold Pro Blood Collection Tubes) with the QuantiFERON-TB Gold Plus Test
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Microbiology
Decision date
Nov 21, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P010033/S051
Regulatory pathway
PMA supplement
Applicant
Qiagen
Product code
NCD
Decision code
APPR
Decision date
Nov 21, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS.

Applicant
Qiagen
Product code
NCD
FDA device class
3

For the original device and its historical approval scope, see PMA P010033. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P010033 · Original PMA

    QUANTTFERON-TB GOLD AND TB GOLD-IN-THE-TUBE

  2. P010033/S051 received

    Application receipt date recorded by FDA.

  3. P010033/S051 · FDA decision

    Real-Time Process

  4. P010033/S052 · Related supplement

    QuantiFERON-TB Gold Test and QuantiFERON-TB Gold Plus Test

  5. P010033/S053 · Related supplement

    QuantiFERON-TB Gold Plus Test

Timeline entries are records held by MedtechLedger for P010033. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010033

Product / regulatory recordCompanyPathwayDecision dateSource
QiagenPMA approvalNov 28, 2001FDA
QiagenPMA supplementJan 23, 2026FDA
QiagenPMA supplementOct 14, 2026FDA

Explore the linked device profile

Other records with product code NCD

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Qiagen

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
19300 Germantown Rd., Germantown, MD, 20874

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records